Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Viewpoint

Vol. 150 No. 4344 (2020)

The prescription retroscope – tools for advocating critical and individualised therapy

DOI
https://doi.org/10.4414/smw.2020.20342
Cite this as:
Swiss Med Wkly. 2020;150:w20342
Published
29.10.2020

References

  1. Levine HJ. Rest heart rate and life expectancy. J Am Coll Cardiol. 1997;30(4):1104–6.
  2. Cook S, Togni M, Schaub MC, Wenaweser P, Hess OM. High heart rate: a cardiovascular risk factor? Eur Heart J. 2006;27(20):2387–93. doi:.https://doi.org/10.1093/eurheartj/ehl259
  3. Palatini P, Benetos A, Grassi G, Julius S, Kjeldsen SE, Mancia G, et al.; European Society of Hypertension. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens. 2006;24(4):603–10. doi:.https://doi.org/10.1097/01.hjh.0000217838.49842.1e
  4. Cook S, Hess OM. Resting heart rate and cardiovascular events: time for a new crusade? Eur Heart J. 2010;31(5):517–9. doi:.https://doi.org/10.1093/eurheartj/ehp484
  5. Messerli FH, Rimoldi SF, Bangalore S, Bavishi C, Laurent S. When an Increase in Central Systolic Pressure Overrides the Benefits of Heart Rate Lowering. J Am Coll Cardiol. 2016;68(7):754–62. doi:.https://doi.org/10.1016/j.jacc.2016.03.610
  6. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279(23):1903–7. doi:.https://doi.org/10.1001/jama.279.23.1903
  7. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al.; REACH Registry Investigators. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340–9. doi:.https://doi.org/10.1001/jama.2012.12559
  8. Johansson S, Rosengren A, Young K, Jennings E. Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. BMC Cardiovasc Disord. 2017;17(1):53. doi:.https://doi.org/10.1186/s12872-017-0482-9
  9. Bruggmann C, Fournier S, Panchaud A, Muller O, Sadeghipour F, Voirol P. Beta-blocker use and up-titration after acute ST-segment elevation myocardial infarction: a cohort study. Swiss Med Wkly. 2020;150:w20321.doi:.https://doi.org/10.4414/smw.2020.20321
  10. Kontos MC, Diercks DB, Ho PM, Wang TY, Chen AY, Roe MT. Treatment and outcomes in patients with myocardial infarction treated with acute β-blocker therapy: results from the American College of Cardiology’s NCDR(®). Am Heart J. 2011;161(5):864–70. doi:.https://doi.org/10.1016/j.ahj.2011.01.006
  11. Airaksinen KE. Autonomic mechanisms and sudden death after abrupt coronary occlusion. Ann Med. 1999;31(4):240–5. doi:.https://doi.org/10.3109/07853899908995886
  12. Messerli FH, Suter T, Bangalore S. What Ever Happened to Cardioprotection With β-Blockers? Mayo Clin Proc. 2018;93(4):401–3. doi:.https://doi.org/10.1016/j.mayocp.2018.02.020
  13. Messerli FH, Messerli AW. Alter ego(s) in coronary artery disease: Insights from a recently departed patient. Eur Heart J. 2018;39(45):3987–98. doi:.https://doi.org/10.1093/eurheartj/ehy701
  14. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al.; ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29(23):2909–45. doi:.https://doi.org/10.1093/eurheartj/ehn416
  15. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al.; Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2003;24(1):28–66. doi:.https://doi.org/10.1016/S0195-668X(02)00618-8
  16. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al.; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77. doi:.https://doi.org/10.1093/eurheartj/ehx393
  17. Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, et al., Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–619. doi:.https://doi.org/10.1093/eurheartj/ehs215
  18. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 1997;349(9049):375–80. doi:.https://doi.org/10.1016/S0140-6736(97)80008-6
  19. Cook S. Heart rate, coronary artery disease and plaque rupture - myth, hype, or truth? Swiss Med Wkly. 2012;142:w13661. doi:.https://doi.org/10.4414/smw.2012.13661
  20. Roolvink V, Ibáñez B, Ottervanger JP, Pizarro G, van Royen N, Mateos A, et al.; EARLY-BAMI Investigators. Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention. J Am Coll Cardiol. 2016;67(23):2705–15. doi:.https://doi.org/10.1016/j.jacc.2016.03.522
  21. Korhonen MJ, Robinson JG, Annis IE, Hickson RP, Bell JS, Hartikainen J, et al. Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction. J Am Coll Cardiol. 2017;70(13):1543–54. doi:.https://doi.org/10.1016/j.jacc.2017.07.783
  22. Dahl Aarvik M, Sandven I, Dondo TB, Gale CP, Ruddox V, Munkhaugen J, et al. Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2019;5(1):12–20. doi:.https://doi.org/10.1093/ehjcvp/pvy034
  23. Argulian E, Bangalore S, Messerli FH. Misconceptions and Facts About Beta-Blockers. Am J Med. 2019;132(7):816–9. doi:.https://doi.org/10.1016/j.amjmed.2019.01.039
  24. Wienbergen H, Zeymer U, Gitt AK, Juenger C, Schiele R, Heer T, et al.; MITRA PLUS Study Group. Prognostic impact of acute beta-blocker therapy on top of aspirin and angiotensin-converting enzyme inhibitor therapy in consecutive patients with ST-elevation acute myocardial infarction. Am J Cardiol. 2007;99(9):1208–11. doi:.https://doi.org/10.1016/j.amjcard.2006.12.036
  25. Grall S, Biere L, Le Nezet M, Bouvier JM, Lucas-Chauvelon P, Richard C, et al. Relationship between beta-blocker and angiotensin-converting enzyme inhibitor dose and clinical outcome following acute myocardial infarction. Circ J. 2015;79(3):632–40. doi:.https://doi.org/10.1253/circj.CJ-14-0633
  26. Pedersen SB, Nielsen JC, Bøtker HE, Goldberger JJ. Beta-Blocker Therapy Early After Myocardial Infarction: A Comparison Between Medication at Hospital Discharge and Subsequent Pharmacy-Dispensed Medication. Drugs Real World Outcomes. 2016;3(3):279–88. doi:.https://doi.org/10.1007/s40801-016-0079-0
  27. Arnold SV, Spertus JA, Masoudi FA, Daugherty SL, Maddox TM, Li Y, et al. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction. J Am Coll Cardiol. 2013;62(19):1791–801. doi:.https://doi.org/10.1016/j.jacc.2013.04.102
  28. Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J. 1999;1:H64–9.
  29. Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, Coats AJ, et al., Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA. 2003;289(6):712–8. doi:.https://doi.org/10.1001/jama.289.6.712
  30. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–7. doi:.https://doi.org/10.1016/S0140-6736(99)04440-2
  31. Amsterdam EA, Gorlin R, Wolfson S. Evaluation of long-term use of propranolol in angina pectoris. JAMA. 1969;210(1):103–6. doi:.https://doi.org/10.1001/jama.1969.03160270065012